Mayne And Mithra Receive Australian Nextstellis Approval
Launch Expected In Mid-2022 After TGA Endorses Estetrol/Drospirenone Contraceptive
Executive Summary
Mayne Pharma and Mithra have revealed launch plans in Australia for their Nextstellis oral contraceptive that combines the novel estrogen estetrol with drospirenone, following approval by the TGA.